Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Exploiting the Biology of Renal Cell Carcinoma: From the Laboratory to Practice

Release Date: March 20, 2009| Expiration Date: March 20, 2010
1.25 AMA PRA Category 1 Credit(s)™| Feb 25, 2009, Orlando, FL

Lecture Overview

Exploiting the Biology of Renal Cell Carcinoma: From the Laboratory to Practice provides a comprehensive review of current therapeutic standards for advanced/metastatic kidney cancer and an in-depth examination of evolving treatment approaches to the clinical management of this patient population in the era of targeted therapy. In particular, issues important for formulating individualized and optimized patient therapy will be addressed, including the comparative advantages and disadvantages of different agents in different patient subpopulations, the optimal sequencing of targeted therapies, the safety and efficacy of combination therapies, and the potential impact of new agents entering the clinic on existing treatment strategies. This program will feature exciting information on the biologic underpinnings of newer therapies in order to engage the audience in the theme of “from the laboratory to practice.” Case-based clinical scenarios will provide context for interpreting and evaluating the presented data as well as reinforcing the information through its application

This satellite symposium is designed to be of high clinical utility to medical oncologists, surgical oncologists, and radiation oncologists involved in the treatment of renal cell carcinoma. Fellows, oncology physician assistants, oncology nurses, and research nurses with an interest in the treatment of patients with renal cell carcinoma are also invited to participate. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.

Upon completion of this educational activity, you should be able to:

  • Incorporate knowledge regarding the role of the vascular growth factor receptor and PI3K/Akt signaling pathways in the pathobiology of metastatic renal cell carcinoma into the interpretation of efficacy and toxicity data from clinical trials evaluating targeted agents
  • Incorporate the proposed treatment algorithm for advanced/metastatic renal cell carcinoma, based on patient risk, treatment history, and evidence from clinical trials, into formulating treatment decisions in daily practice, including the use of FDA-approved targeted agents
  • Formulate treatment strategies using the optimal sequence of targeted agents for individualized therapy in refractory/recurrent disease
  • Assess the potential roles of second-generation orally available targeted agents still undergoing clinical development in the treatment of renal cell carcinoma and their placement in the proposed treatment algorithm
  • Compare the utility of sequential monotherapy to that of combination therapy with targeted agents in maximizing clinical benefit in patients with advanced renal cell carcinoma

Instructions for Participation

  1. Read the following information before beginning the educational activity.
  2. Complete the Pretest.
  3. View and study all Flash video presentations.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

Accreditation and Credit Designation

Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.

Complete the test(s) and evaluation by March 20, 2010 to receive your certificate online.

Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from the Exploiting the Biology of Renal Cell Carcinoma: From the Laboratory to Practice symposium have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

Robert A. Figlin, MD, FACP
Paid Consultant/Advisory Board – AVEO Pharmaceuticals, Inc., Wyeth Pharmaceuticals; Research Funding – Amgen, Antisoma plc, Argos Therapeutics, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc., Wyeth Pharmaceuticals

Gary Hudes, MD
Paid Consultant/Advisory Board – Genentech, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Wyeth Pharmaceuticals

Roberto Pili, MD
Research Funding – Celgene Corporation; Locus Pharmaceuticals, Inc.; Pfizer Inc.

David I. Quinn, MBBS, PhD, FRACP
Paid Consultant/Advisory Board – Abbott Laboratories, Bayer Pharmaceuticals Corporation, Genentech, Inc., Onyx Pharmaceuticals, Inc., Pfizer Inc., sanofi-aventis U.S., Watson Pharmaceuticals Inc., Wyeth Pharmaceuticals; Speaker’s Bureau – Bayer Pharmaceuticals Corporation, Eli Lilly and Company, Millennium Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, Inc., Pfizer Inc., sanofi-aventis U.S., Watson Pharmaceuticals Inc.; Research Funding – Genentech, Inc., Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., sanofi-aventis U.S.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your software, follow one of the links listed below:

Macintosh Users
Compatible software includes:

Disclaimer

The views and opinions expressed in this learning activity are those of the presenters and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the presenters and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Privacy Policy

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

©Copyright 2009 by Physicians’ Education Resource.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

All correspondence should be directed to:
Editor, Exploiting the Biology of Renal Cell Carcinoma: From the Laboratory to Practice
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

Educational Grants

An educational grant for this activity was provided by:


  1. Novartis Oncology